Levodril

Levodropropizine, the active ingredient in Levodril, is an antitussive presented as an oral dosage form for oral use. It suppresses cough reflexes and is indicated for the relief of dry or non‑productive cough in adults and children.

GNH USA supplies Levodril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for global healthcare providers. Levodril is manufactured under EU GMP guidelines and exported to multiple regions under appropriate regulatory frameworks.

Levodropropizine is an antitussive that acts on the peripheral cough reflex pathway.

Dry cough: reduces the frequency and intensity of non‑productive cough episodes. Cough: provides symptomatic relief of acute cough in adults and children. Irritant cough: alleviates cough triggered by throat irritation.

Levodropropizine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools occurring intermittently. - Dizziness: transient light‑headedness. - Headache: mild frontal or occipital pain. - Taste alteration: temporary metallic or bitter taste. - Fatigue: mild feeling of tiredness.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, swelling, or difficulty breathing. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Severe gastrointestinal bleeding: uncommon but possible. - Anaphylaxis: rapid onset of systemic allergic response. - Cardiac arrhythmia: rare irregular heartbeat. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Levodropropizine, clinicians should consider the following safety measures.

Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. Breastfeeding: assess risk versus benefit, as the drug may be excreted in milk. Renal impairment: dose adjustment may be required in severe cases. Hepatic impairment: monitor liver function tests during therapy. Concomitant CNS depressants: observe for additive sedation, although central effects are minimal. Store at ambient temperature: keep below 25°C, retain in original packaging, and protect from moisture.

Levodropropizine may interact with other medicines; awareness of the interaction level helps guide clinical decisions.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of heightened serotonergic effects. - Strong CYP450 inhibitors: may increase plasma concentrations of levodropropizine.

Moderate Interactions (Monitor Closely): - Antihistamines: possible additive antitussive effect leading to excessive cough suppression. - Sedative agents: monitor for enhanced drowsiness. - Other peripheral antitussives: avoid cumulative dosing. - Herbal products containing menthol: may potentiate local irritation. - Acid‑reducing agents: could alter absorption profile.